Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $2.8 million.

  • Biodesix's Current Deferred Revenue rose 30000.0% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 30000.0%. This contributed to the annual value of $700000.0 for FY2024, which is 11604.94% up from last year.
  • Per Biodesix's latest filing, its Current Deferred Revenue stood at $2.8 million for Q3 2025, which was up 30000.0% from $617000.0 recorded in Q2 2025.
  • In the past 5 years, Biodesix's Current Deferred Revenue ranged from a high of $2.8 million in Q3 2025 and a low of $313000.0 during Q1 2024
  • Its 5-year average for Current Deferred Revenue is $1.3 million, with a median of $1.1 million in 2023.
  • As far as peak fluctuations go, Biodesix's Current Deferred Revenue tumbled by 7237.42% in 2024, and later soared by 30000.0% in 2025.
  • Biodesix's Current Deferred Revenue (Quarter) stood at $1.9 million in 2021, then crashed by 47.37% to $1.0 million in 2022, then crashed by 67.6% to $324000.0 in 2023, then skyrocketed by 116.05% to $700000.0 in 2024, then skyrocketed by 300.0% to $2.8 million in 2025.
  • Its Current Deferred Revenue stands at $2.8 million for Q3 2025, versus $617000.0 for Q2 2025 and $800000.0 for Q1 2025.